Crystal structures of dipeptides containing the Dmt-Tic pharmacophore

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5506-5513

  Bryant, Sharon D ^a   George, Clifford ^b   Flippen Anderson, Judith L ^b   Deschamps, Jeffrey R ^b   Salvadori, Severo ^c   Balboni, Gianfranco ^d   Guerrini, Remo ^c   Lazarus, Lawrence H ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; DELTA OPIATE RECEPTOR; DIPEPTIDE;

ARTICLE; ATOM; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFUSION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG SYNTHESIS; EVAPORATION; HYDROGEN BOND; HYDROPHOBICITY; METHYLATION; MOLECULE; PHARMACOPHORE; RECEPTOR AFFINITY; X RAY ANALYSIS; X RAY DIFFRACTION;

ADAMANTANE; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; ISOQUINOLINES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OPIOID PEPTIDES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TYROSINE;

EID: 0037027992     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020330p     Document Type: Article

References (53)

1. 2,5]enkephalin, H-Tyr-[D-Pen-Gly-Phe-D-Pen]-OH; JOM-13, Tyr-c[D-Cys-Phe-D-Pen]OH; OtBu, tert-butyl ester; Fmoc, 9-fluoroenylmethyloxycarbonyl; GPI, guinea pig ileum; MVD, mouse vas deferens; HOBt, 1-hydroxybenzotriazole; Pen, β,β-dimethylcysteine; TIPP, H-Tyr-Tic-Phe-Phe-OH.
2. Atweh, S. F.; Kuhar, M. J. Distribution and physiological significance of opioid receptors in the brain. Br. Med. Bull. 1983, 39, 57-59.
3. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; Morris, H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975, 258, 577-580.
4. Li, C. H.; Chung, D. Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 1145-1148.
5. Goldstein, A.; Tachibana, S.; Lowney, L. H.; Hunkapiller, M.; Hood, L. Dynorphin-(1-13), an extraordinary potent opioid peptide. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 6666-6670.
6. Zadina, J. E.; Hackler, L.; Gee, L. J., Kastin, A. J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997, 386, 499-502.
7. Mercadante, S.; Villari, P.; Ferrera, P.; Casuccio, A.; Fulfaro, F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002, 95, 203-208.
8. Kelly, A. M.; Koutsogiannis, Z. Intranasal naloxone for life threatening opioid toxicity. Emerg. Med. J. 2002, 19, 375.
9. Gowing, L.; Ali, R.; White, J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst. Rev. 2002, 2, CD001333.
10. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21, 1663-1671.
11. Santagada, V.; Balboni, G.; Caliendo, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Bryant, S. D.; Lazarus, L. H. Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorg. Med. Chem. Lett. 2000, 10, 2745-2748.
12. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
13. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ opioidmimetic antagonists: Prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
14. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discovery Today 1998, 3, 284-294.
15. Chandrakumar, N. S.; Yonan, P. K.; Stapelfeld, A.; Savage, M.; Rorbacher, E.; Contreras, P. C.; Hammond, D. Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide. J. Med. Chem. 1992, 35, 223-233.
16. 5]enkephalin. J. Med. Chem. 1992, 35, 684-687.
17. Pitzele, B. S.; Hamilton, R. W.; Kudla, K. D.; Tsymbalov, S.; Stapelfeld, A.; Savage, M. A.; Clare, M.; Hammond, D. L.; Hansen, J. D. W. Enkephalin analogs as systematically active antinociceptive agents: O- and N-alkylated derivatives of the dipeptide amide L-2,6-dimethyltyrosyl-N-(3-phenylpropyl)-D-alaninamide. J. Med. Chem. 1994, 37, 888-896.
18. Guerrini, R.; Capasso, A.; Sorrentino, L.; Anacardio, R.; Bryant, S. D.; Lazarus, L. H.; Attila, M.; Salvadori, S. Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmtl]deltorphin B. Eur. J. Pharmacol. 1996, 302, 37-42.
19. Guerrini, R.; Capasso, A.; Marastoni, A.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. Rational design of dynorphin A analogues with δ-receptor selectivity and antagonism for δ- and κ-receptors. Bioorg. Med. Chem. 1998, 6, 57-62.
20. Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Biological properties of opioid peptides replacing Tyr at position 1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1507.
21. Schiller, P. W.; Nguyen, T. M.-D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N. N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 2000, 35, 895-901.
22. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: Hydrophobic substituents at the C-terminus endows δ antagonists to manifest μ agonism or μ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
23. Page, D.; McClory, A.; Mischki, T.; Schmidt, R.; Butterworth, J.; St-Onge, S.; Labarre, M.; Payza, K.; Brown, W. Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 167-170.
24. Page, D.; Naismith, A.; Schmidt, R.; Coupal, M.; Labarre, M.; Gosselin, M.; Bellemare, D.; Payza, K.; Brown, W. Novel Cterminus modifications of the Dmt-Tic motif: A new class of dipeptide analogues showing altered pharmacological profiles toward the opioid receptors. J. Med. Chem. 2001, 44, 2387-2390.
25. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
26. Crescenzi, O.; Fraternali, F.; Picone, D.; Tancredi, T.; Balboni, G.; Guerrini, R.; Lazarus, L. H.; Salvadori, S.; Temussi, P. A. Design and solution structure of a partially rigid opioid antagonist lacking the basic center. Eur. J. Biochem. 1997, 247, 66-73.
27. Bryant, S. D.; Balboni, G.; Guerrini, R.; Salvadori, S.; Tomatis, R.; Lazarus, L. H. Opioid diketopiperazines: Refinement of the δ opioid antagonist pharmacophore. Biol. Chem. 1997, 378, 107-114.
28. Bryant, S. D.; Salvadori, S.; Cooper, P. S.; Lazarus, L. H. New δ opioid antagonists as pharmacological probes. Trends Pharmacol. Sci. 1998, 19, 42-46.
29. Santagada, V.; Caliendo, G.; Severino, B.; Perissutti, E.; Ceccarelli, F.; Giusti, L.; Mazzoni, R.; Salvadori, S.; Temussi, P. A. Probing the shape of a hydrophobic pocket in the active site of δ-opioid antagonists. J. Pept. Sci. 2001, 7, 374-385.
30. Spadaccini, R.; Temussi, P. A. Natural peptide analgesics: The role of solution conformation. Cell. Mol. Life Sci. 2001, 58, 1572-1582.
31. Flippen-Anderson, J. L.; George, C.; Deschamps, J. R.; Reddy, P. A.; Lewin, A. H.; Brine, G. A. X-Ray structures of the δ opioid antagonist TIPP and a protected derivative of the δ antagonist ICI 174,864. Lett. Pept. Sci. 1994, 1, 107-115.
32. Flippen-Anderson, J. L.; Deschamps, J. R.; George, C.; Reddy, P. A.; Lewin, A. H.; Brine, G. A.; Sheldrick, G.; Nikiforovich, G. X-Ray structure of Tyr-D-Tic-Phe-Phe-NH2 (D-TIPP-NH2), a highly potent μ-receptor selective opioid agonist. J. Pept. Res. 1997, 49, 384-393.
33. Deschamps, J. R.; Flippen-Anderson, J. L.; Moore, C.; Cudney, R.; George, C. Tyrosinium-D-tetrahydroisoquinoline-3-carbox-ylate 1,5-hydrate and tyrosyl-D-tetrahydroisoquinoline-3-carboxamide hydrate. Acta Crystallogr. C 1997, C53, 1478-1482.
34. 2]deltorphin I: Effects on opioid receptor affinities and activities in vitro and on antinociceptive potency. Peptides 1997, 18, 1615-1621.
35. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Salvadori, S. What peptides these deltorphins be. Prog. Neurobiol. 1999, 57, 377-420.
36. Mosberg, H. I.; Ho, J. C.; Sobczyk-Kojiro, K. A high affinity, muopioid receptor-selective enkephalin analogue lacking an N-terminal tyrosine. Bioorg. Med. Chem. Lett. 1998, 8, 2681-2684.
37. Goodman, M.; Ro, S.; Osapay, G.; Yamazaki, T.; Polinsky, A. The molecular basis of opioid potency and selectivity: Mophiceptins, dermorphins, deltorphins, and enkephalins. NIDA Res. Monogr. 1993, 143, 195-209.
38. Bryant, S. D.; Attila, M.; Salvadori, S.; Guerrini, R.; Lazarus, L. H. Molecular dynamics conformations of deltorphin analogues advocate δ opioid binding site models. Pept. Res. 1994, 7, 175-184.
39. Bryant, S. D.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Tomatis, R.; Attila, M.; Lazarus, L. H. Helix inducing α-aminoisobutyric acid in opioidmimetic deltorphin C analogues. J. Med. Chem. 1997, 40, 2579-2587.
40. Flippen-Anderson, J. L.; Deschamps, J. R.; Ward, K. B.; George, C.; Houghten, R. Crystal structure of deltakephalin: A δ-selective opioid peptide with a novel β-bend-like conformation. Int. J. Pept. Protein Res. 1994, 44, 97-104.
41. Aubry, A.; Birlirakis, N.; Sakarellos-Daitsiotis, M.; Sakarellos, C.; Marraud, M. A crystal molecular conformation of leucine-enkephalin related to the morphine molecule. Biopolymers 1989, 28, 27-40.
42. 2.DMSO. A fragment of a biologically active enkephalin analogue. J. Chem. Soc., Perkins Trans. 1983, 1, 417-421.
43. 3H]: An active synthetic enkephalin analogue. J. Chem. Soc. 1985, 681-682.
44. 5] enkephalin, a highly potent, δ opioid receptor-selective compound: Comparison with proposed solution conformations. J. Am. Chem. Soc. 1994, 116, 7523-7531.
45. 1H NMR data. J. Am. Chem. Soc. 1994, 116, 429-436.
46. Schwyzer, R. Molecular mechanism of opioid selection. Biochemistry 1986, 25, 6335-6342.
47. 3]DPDPE. J. Am. Chem. Soc. 1996, 118, 2143-2152.
48. 5): Novel conformationally constrained opioid peptides. J. Am. Chem. Soc. 1996, 118, 959-969.
49. Deschamps, J. R.; George, C.; Flippen-Anderson, J. L.; DeMilo, A. B.; Bordas, B. X-ray crystallographic and molecular modeling studies of 1-(2,6-diflourobenzoyl)-5-(4-chlorophenyl)biuret. J. Chem. Crystallogr. 1998, 28, 453-459.
50. McPherson, A. Preparation and Analysis of Protein Crystals; John Wiley & Sons: New York, 1982.
51. Ducruix, A., Girge, R. I., Eds. Crystallization of Nucleic Acids and Proteins: A Practical Approach; Oxford University Press: New York, 1992; pp 73-98.
52. Sheldrick, G. M. SHELXTL, Version 5.1; Bruker Analytical X-ray Instruments: Madison, WI, 1997.
53. Bruker SMART and SAINT Data Collection and Reduction Software for the SMART System; Bruker-AXS, Bruker Analytical X-ray Instruments: Madison, WI, 1995.